Last reviewed · How we verify
Prednisone 1
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Lymphoma (as part of combination chemotherapy regimens), Autoimmune and inflammatory disorders.
At a glance
| Generic name | Prednisone 1 |
|---|---|
| Also known as | Deltasone |
| Sponsor | Polish Lymphoma Research Group |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Prednisone acts as a glucocorticoid receptor agonist, inhibiting the production of pro-inflammatory cytokines and reducing immune cell activation. It decreases lymphocyte proliferation and function, making it effective for managing autoimmune and inflammatory conditions. In lymphoma treatment, it is often used as part of combination chemotherapy regimens to enhance efficacy and manage treatment-related inflammation.
Approved indications
- Lymphoma (as part of combination chemotherapy regimens)
- Autoimmune and inflammatory disorders
Common side effects
- Immunosuppression / increased infection risk
- Hyperglycemia
- Osteoporosis
- Insomnia
- Mood changes
- Hypertension
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisone 1 CI brief — competitive landscape report
- Prednisone 1 updates RSS · CI watch RSS
- Polish Lymphoma Research Group portfolio CI